- Home
- CRGX vs IRMD Comparison
CRGX vs IRMD Comparison
Compare CRGX & IRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- IRMD
- Stock Information
- Founded
- CRGX 2021
- IRMD 1992
- Country
- CRGX United States
- IRMD United States
- Employees
- CRGX N/A
- IRMD N/A
- Industry
- CRGX
- IRMD Medical/Dental Instruments
- Sector
- CRGX
- IRMD Health Care
- Exchange
- CRGX Nasdaq
- IRMD Nasdaq
- Market Cap
- CRGX 621.4M
- IRMD 766.5M
- IPO Year
- CRGX 2023
- IRMD 2014
- Fundamental
- Price
- CRGX $13.46
- IRMD $60.48
- Analyst Decision
- CRGX Strong Buy
- IRMD Strong Buy
- Analyst Count
- CRGX 6
- IRMD 1
- Target Price
- CRGX $31.80
- IRMD $60.00
- AVG Volume (30 Days)
- CRGX 231.3K
- IRMD 34.8K
- Earning Date
- CRGX 03-20-2025
- IRMD 02-06-2025
- Dividend Yield
- CRGX N/A
- IRMD 0.99%
- EPS Growth
- CRGX N/A
- IRMD 13.16
- EPS
- CRGX N/A
- IRMD 1.46
- Revenue
- CRGX N/A
- IRMD $71,305,130.00
- Revenue This Year
- CRGX N/A
- IRMD $13.60
- Revenue Next Year
- CRGX N/A
- IRMD $10.46
- P/E Ratio
- CRGX N/A
- IRMD $41.43
- Revenue Growth
- CRGX N/A
- IRMD 13.23
- 52 Week Low
- CRGX $10.91
- IRMD $40.18
- 52 Week High
- CRGX $33.92
- IRMD $61.00
- Technical
- Relative Strength Index (RSI)
- CRGX 47.00
- IRMD 68.24
- Support Level
- CRGX $12.51
- IRMD $59.25
- Resistance Level
- CRGX $15.75
- IRMD $61.00
- Average True Range (ATR)
- CRGX 1.09
- IRMD 1.62
- MACD
- CRGX 0.17
- IRMD 0.31
- Stochastic Oscillator
- CRGX 52.74
- IRMD 92.00
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
About IRMD iRadimed Corporation
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.